MSCLF Message Board Post 10722944 | iCo Therapeutics
home / stock / msclf / msclf message board
charles900
(investorshangout)
Posted on: Jun/30/2018 16:34:54
Source: investorshangout
https://investorshangout.com/post/view?id=5111398
Mr.Wonderful: iCo meets primary end point for iCo-019 study 2018-06-27 09:53 ET - News Release Shares issue
News, Short Squeeze, Breakout and More Instantly...
-
– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) ...
-
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
-
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...